NCLAT: Corporate Debtor’s Guarantor Liability Unchanged Despite Internal Adjustments Among Creditors  ||  NCLAT: Plea under IBC Section 7 Can't Be Restored After Corporate Debtor Pays Principal & Interest  ||  Delhi HC: Wife Can Be Denied Maintenance If She Fails To Submit Latest Salary Slips  ||  Kerala HC: Income of Parent Who Abandoned Family Shouldn’t Count For EWS Reservation Eligibility  ||  Gujarat HC: Writ Courts Interfering in Arbitral Procedure Orders Defies A&C Act’s Purpose  ||  Delhi HC: Plaintiff Doesn’t Have Vested Right to File Rejoinder under CPC  ||  J&K&L HC: Name Change Is Fundamental Right; Boards Must Consider Legal Documents, Not Reject Request  ||  SC: Administrative Delays by State Agencies Must Not Be Condoned  ||  Sc: When Sale Deed Is Void, Possession Suit Follows 12-Year Limitation under Article 65, Not Art 59  ||  SC: Preliminary Inquiry Report Can’t Stop Court from Directing FIR Registration    

Commerce Minister releases study report on Indian pharma exports to China- (Press Information Bureau) (18 Jun 2018)

MANU/PIBU/0962/2018

Commercial

For India to make a strong pitch for pharma exports to China, the Department of Commerce in coordination with Embassy of India at Beijing commissioned a study on "Enhancing Indian Exports of Pharmaceutical products to China" under the Market Access Initiative Scheme (MAI) to have a proper understanding of Chinese market and to help the Indian pharma industry to evolve appropriate and focused strategy for entry of the Indian generic drugs.

The study examines the health care market, pharmaceutical market the distribution system, procurement and bidding process and the regulatory landscape in China. The study also gives recommendations on how to access the Chinese market.

China' s health-care sector continues to grow rapidly with spending projected to grow from $ 357 billion in 2011 to $ 1 trillion in 2020. From pharmaceuticals to medical products to consumer health, China remains among the world's most attractive markets, and by far the fastest-growing of all the large emerging ones.

The study has been done by IMS Health team which worked with PHARMEXCIL and Industry stakeholders.

Tags : CHINA   PHARMA   EXPORT  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved